Pipeline & Data

With an eye on the future™

our retinal disease–focused pipeline is designed to provide solutions for patients. When it comes to matters of sight, innovation is our vision.

wet AMD=wet age-related macular degeneration; EOP2=End of Phase 2; FPI=first patient in; NPDR=non-proliferative diabetic retinopathy; DME=diabetic macular edema; GA=geographic atrophy.

EYP-1901

VEGF Receptor Binding Vorolanib In Bioerodible Durasert E™

  • Positive efficacy data in wet AMD from Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials
  • Favorable safety profile with no ocular or systemic EYP-1901-related SAEs reported in ongoing Phase 2 clinical trials
  • Immediately bioavailable featuring an initial burst of drug followed by zero order kinetics release for ~9 months
  • Vorolanib fully eluted prior to complete bioerosion of the matrix to control release and allow redosing regimen
  • Delivered in the physician office via routine intravitreal injection
  • Shipped and stored at ambient temperature

With EYP-1901, a solution is possible through sustained, stable release that may lead to better visual outcomes

Clinical Trials - EYP-1901

Phase 2 DAVIO 2 Clinical Trial Topline Results (Wet AMD)

A Non-inferiority Trial Evaluating Two Doses of EYP-1901 Against an Aflibercept Control in Wet AMD

Phase 2 DAVIO 2 Sub-Group Analysis (Wet AMD)

Patients Anti-VEGF Supplement-Free Up to 6 Months

Phase 2 PAVIA Clinical Trial in Non-Proliferative Diabetic Retinopathy (NPDR)

Randomized Double-Masked, EYP-1901 Single Injection with Sham Control as a 9-Month Treatment in NPDR

Phase 2 VERONA Clinical Trial in Diabetic Macular Edema (DME)

Randomized, Open-Label, Aflibercept Controlled Trial with a Single EYP-1901 Injection

Phase 2 DAVIO 2 Clinical Trial Topline Results (Wet AMD)

A Non-inferiority Trial Evaluating Two Doses of EYP-1901 Against an Aflibercept Control in Wet AMD

Phase 2 DAVIO 2 Sub-Group Analysis (Wet AMD)

Patients Anti-VEGF Supplement-Free Up to 6 Months

Phase 2 PAVIA Clinical Trial in Non-Proliferative Diabetic Retinopathy (NPDR)

Randomized Double-Masked, EYP-1901 Single Injection with Sham Control as a 9-Month Treatment in NPDR

Phase 2 VERONA Clinical Trial in Diabetic Macular Edema (DME)

Randomized, Open-Label, Aflibercept Controlled Trial with a Single EYP-1901 Injection

EYP-2301

Razuprotafib in Durasert E™ is Being Developed as a Sustained Delivery Treatment for Serious Retinal Diseases

  • Tie-2 activation combined with VEGF inhibition has the potential to enhance efficacy and extend durability of treatment1,2
  • In the retina, activated TIE-2 controls endothelial cell proliferation, barrier function and intercellular contacts, stabilizing vessels and the blood-retinal barrier3
  • Razuprotafib (f/k/a AKB-9778) delivered subcutaneously was previously studied demonstrating preclinical and clinical proof of concept in posterior segment disease4,5

EYP-2301 targets vascular endothelial protein tyrosine phosphatase (VE-PTP) to promote TIE2 activation and maintain vascular stability in the retina

In the retina, activated Tie2 controls endothelial cell proliferation, barrier function, and intercellular contacts, stabilizing vessels and the blood-retinal barrier3

A clinical trial (TIME-2) demonstrated that razuprotafib combined with VEGF inhibition can improve efficacy in DME patients5

References: 1. Heier JS, et al. Retina. 2021;41(1):1-19. 2. Joussen et al. Eye (Lond). 2021;35(5):1305-1316. 3. Hammes HP, et al. Diabetes. 2011;60(1):9-16. 4. Shen J, et al. J Clin Invest. 2014;124(10):4564-4576. 5. Campochiaro PA, et al. Ophthalmology. 2016;123(8):1722-1730.